Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5935
    +0.0001 (+0.02%)
     
  • NZD/EUR

    0.5543
    +0.0002 (+0.04%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.84
    -0.52 (-0.62%)
     
  • GOLD

    2,328.90
    -13.20 (-0.56%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • NZD/JPY

    92.0830
    +0.3170 (+0.35%)
     

Company News For Dec 14, 2017

Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
  • Shares of Civitas Solutions Inc CIVI declined 10% after reporting fourth quarter 2017 revenues of $380 million, lower than the Zacks Consensus Estimate of $388 million

  • Cellectis S.A.’s CLLS shares gained 11.6% after reporting positive results from 2 acute lymphoblastic leukemia trials of Servier and Pfizer's UCART19 product

  • Shares of VeriFone Systems, Inc. PAY declined 3.8% after the company issued FY 2018 EPS guidance in the range of $1.47-$1.50 per share, lower than the Zacks Consensus Estimate of $1.57

  • Finisar Corporation’s FNSR gained 22.8% after the company announced that it would receive a $390 million award from Apple AAPL


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Verifone Systems, Inc. (PAY) : Free Stock Analysis Report
 
Apple Inc. (AAPL) : Free Stock Analysis Report
 
Finisar Corporation (FNSR) : Free Stock Analysis Report
 
Cellectis S.A. (CLLS) : Free Stock Analysis Report
 
Civitas Solutions, Inc. (CIVI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research